Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony
Stephen MacMillan, Hologic President and CEO, to highlight the important benefits of Hologic's 3D Mammography solution for breast cancer screening and diagnosis

BEDFORD, Mass., Sept. 30, 2014 /PRNewswire/ -- Hologic, Inc. (NASDAQ: HOLX), today announced that Stephen MacMillan, Hologic's President and Chief Executive Officer, will preside over the NASDAQ Stock Market Opening Bell Ceremony on October 1, the first day of Breast Cancer Awareness Month. In his remarks, Mr. MacMillan will discuss the Company's campaign focused on the important benefits of Hologic's 3D Mammography technology, the only 3D system approved by the FDA as clinically superior to traditional mammography.

This is the ninth consecutive year that Hologic has been invited to participate in the NASDAQ Opening Bell Ceremony on the first business day in October.

"It is an honor to host the NASDAQ Opening Bell Ceremony on the first day of Breast Cancer Awareness Month," said Mr. MacMillan. "We are committed to developing technologies that detect diseases earlier and improve patient outcomes. Our 3D mammography technology is truly revolutionary. It addresses the limitations of traditional mammography – the over-diagnosis of non-invasive cancers and unnecessary recalls for additional testing – with the demonstrated ability to increase the detection rate of invasive cancers. It is the first and only 3D system that is clinically proven to be superior to traditional 2D mammography. Throughout October, we will focus on encouraging women to become their own advocates, by taking control of their health and learning more about this game-changing technology. Hologic's 3D Mammography is an important new tool in the treatment of breast cancer that empowers doctors to have greater confidence in their diagnoses and patients to have greater confidence in the results."

Hologic's 3D Mammography Technology:

Hologic was the first company to receive FDA approval for its 3D mammography system. This technology was approved for breast cancer screening and diagnosis in the U.S. in February 2011 and has been available in countries recognizing the CE mark since 2008. Hologic offers a comprehensive 3D platform including low-dose 3D mammography, as well as the first FDA approved 3D-guided breast biopsy system.

Hologic's groundbreaking 3D mammography exam is the only one approved as clinically superior to traditional mammography by the FDA. Unlike conventional 2D mammography where the presence of overlapping breast tissue can make it more difficult to detect cancer, Hologic's 3D technology is designed to allow doctors to see the breast more clearly for all women. As a result, fewer women are called back for additional testing due to false positive results. Since 2011, over 8 million women in the U.S. have benefited from Hologic's 3D Mammography.

Hologic's 3D Mammography technology is in use in all 50 states and more than 50 countries. Additional information, as well as Hologic's 3D site finder, can be found at

Webcast Information:

The Hologic NASDAQ Stock Market Opening Bell Ceremony will be aired live at (access this by clicking on the MarketSite live webcam) and will also be aired with closed captioning on the NASDAQ MarketSite Tower in Times Square. A video of the Opening Bell ceremony will be archived for one year on the NASDAQ site.

About Hologic, Inc.:

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure. For more information on Hologic, visit

Hologic, 3D Mammography, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. 

Forward-looking Statement Disclaimer:

This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic 3D Mammography systems. There can be no assurance the systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statements are based.




Deborah Gordon                                      

Jim Culley

Vice President, Investor Relations &          

Senior Director, Corporate Communications

Corporate Communications                  

(781) 999-7716                                 

(302) 528-1312        

Marianne McMorrow

Manager, Corporate Communications

(781) 999-7723


SOURCE Hologic, Inc.